SCHEMBL24724145

SCHEMBL24724145

CC(=O)c1nnc(C2CC2)o1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
MAPT P10636 1/20 0.46
CYP2C19 P33261 1/20 0.39
EPHX2 P34913 2/20 0.38
ATM Q13315 2/20 0.38
NPC1 O15118 1/20 0.38
HPGD P15428 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
PDK1 Q15118 1/20 0.37
PDK2 Q15119 1/20 0.37
ADCY1 Q08828 6/20 0.37
LIPG Q9Y5X9 1/20 0.37
PKM P14618 1/20 0.36
DPP4 P27487 1/20 0.36
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
ADCY8 P40145 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21525527 0.82 ADCY1 (0.39) KMT2AMEN1MAPTCYP2C19EPHX2
SCHEMBL6431313 0.80 CA1 (0.38) KMT2AMEN1MAPTCYP2C19EPHX2
SCHEMBL408407 0.76 PKM (0.41) KMT2AMEN1EPHX2NPSR1ADCY1
SCHEMBL441026 0.71 PKM (0.39) KMT2AMEN1EPHX2NPSR1ADCY1
SCHEMBL408403 0.71 PKM (0.39) KMT2AMEN1EPHX2NPSR1ADCY1
SCHEMBL437764 0.70 PKM (0.38) KMT2AMEN1MAPTEPHX2NPSR1
SCHEMBL24724136 0.68 KDM4E (0.36) KMT2AMEN1MAPTCYP2C19NPSR1
SCHEMBL14959509 0.68 MAPT (0.41) KMT2AMAPTNPC1HPGDNPSR1
SCHEMBL17664676 0.68 ADCY1 (0.38) KMT2AMEN1MAPTCYP2C19NPSR1
SCHEMBL17645770 0.68 CA1 (0.40) KMT2AMEN1MAPTCYP2C19NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240287070-A1 FUSED HETEROCYCLIC DERIVATIVES JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) 2024-08-29 US disclosed
EP-4347590-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2024-04-10 EP disclosed
CN-117715909-A Condensed heterocyclic derivative 杨森科学爱尔兰无限公司 2024-03-15 CN disclosed
WO-2022253259-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2022-12-08 WO disclosed
WO-2022253259-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2022-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287070-A1 FUSED HETEROCYCLIC DERIVATIVES HAVCR2, HCCS, GOT2 KMT2A 3953/4885MEN1 1941/4885MAPT 2596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.